Sanofi (SNY) to Release Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) will be releasing its earnings data before the market opens on Thursday, April 25th. Analysts expect Sanofi to post earnings of $0.99 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Price Performance

Shares of SNY stock opened at $47.15 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 12-month low of $42.63 and a 12-month high of $57.82. The firm has a fifty day moving average of $47.54 and a 200-day moving average of $48.50. The firm has a market capitalization of $119.27 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a $1.478 dividend. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio is 62.29%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SNY shares. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley began coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.